170364-57-5 | Enzastaurin

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$15.00	$10.00
5mg	98%	in stock	$26.00	$18.00
10mg	98%	in stock	$36.00	$25.00
50mg	98%	in stock	$88.00	$62.00
100mg	98%	in stock	$131.00	$92.00
250mg	98%	in stock	$222.00	$155.00

Description

• Catalog Number: AE81331
• Chemical Name: Enzastaurin
• CAS Number: 170364-57-5
• Molecular Formula: C32H29N5O2
• Molecular Weight: 515.605
• MDL Number: MFCD11040980
• SMILES: O=C1NC(=O)C(=C1c1cn(c2c1cccc2)C1CCN(CC1)Cc1ccccn1)c1cn(c2c1cccc2)C

Computed Properties

• Complexity: 974
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 39
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5
• XLogP3: 3.7

Literature

• Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.

  Scientific reports 20140101

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• PROX1 overexpression inhibits protein kinase C beta II transcription through promoter DNA methylation.

  Genes, chromosomes & cancer 20121101

• NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

  Expert opinion on investigational drugs 20121101

• Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma.

  American journal of clinical oncology 20121001

• Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.

  Annals of hematology 20121001

• A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20121001

• A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20121001

• A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120915

• A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.

  Cancer 20120901

• Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.

  Leukemia & lymphoma 20120501

• Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro.

  Endocrinology 20120501

• Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?

  Expert opinion on investigational drugs 20120501

• Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.

  Investigational new drugs 20120401

• A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20120401

• A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).

  Neuro-oncology 20120301

• Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.

  British journal of cancer 20120227

• Novel targeted therapies for mantle cell lymphoma.

  Oncotarget 20120201

• miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.

  PloS one 20120101

• The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.

  PloS one 20120101

• A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.

  Oncology 20120101

• 14-3-3ζ interacts with stat3 and regulates its constitutive activation in multiple myeloma cells.

  PloS one 20120101

• Novel therapies for aggressive B-cell lymphoma.

  Advances in hematology 20120101

• Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.

  PloS one 20120101

• The first European interdisciplinary ewing sarcoma research summit.

  Frontiers in oncology 20120101

• Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.

  Investigational new drugs 20111201

• Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.

  Head & neck 20111201

• Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.

  Neuro-oncology 20111201

• Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.

  British journal of cancer 20111108

• Effects of heme oxygenase-1 on induction and development of chemically induced squamous cell carcinoma in mice.

  Free radical biology & medicine 20111101

• Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.

  Current cancer drug targets 20111101

• Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.

  Current cancer drug targets 20111101

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110901

• Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review.

  Journal of neuro-oncology 20110901

• HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.

  Apoptosis : an international journal on programmed cell death 20110901

• Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma.

  Head & neck 20110801

• Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.

  Endocrine-related cancer 20110801

• Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies.

  Expert opinion on investigational drugs 20110801

• Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.

  Leukemia & lymphoma 20110801

• Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.

  Expert opinion on investigational drugs 20110801

• Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin.

  The Journal of investigative dermatology 20110701

• A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.

  American journal of hematology 20110701

• Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells.

  Journal of cellular biochemistry 20110601

• A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

  Gynecologic oncology 20110601

• Pathway inhibition: emerging molecular targets for treating glioblastoma.

  Neuro-oncology 20110601

• A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.

  Journal of neuro-oncology 20110501

• Impact of metal-induced degradation on the determination of pharmaceutical compound purity and a strategy for mitigation.

  Journal of pharmaceutical and biomedical analysis 20110405

• Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis.

  Journal of hepatology 20110401

• [11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C.

  Bioorganic & medicinal chemistry letters 20110315

• APC +/- alters colonic fibroblast proteome in FAP.

  Oncotarget 20110301

• Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.

  Investigational new drugs 20110201

• The need for third-line treatment in non-small cell lung cancer: an overview of new options.

  Anticancer research 20110201

• p73 as a pharmaceutical target for cancer therapy.

  Current pharmaceutical design 20110201

• The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3β.

  Biochemical pharmacology 20110115

• Growth Inhibition and Induction of Apoptosis in SHG-44 Glioma Cells by Chinese Medicine Formula 'Pingliu Keli'.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.

  Neuro-oncology 20110101

• Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells.

  Korean journal of urology 20110101

• Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.

  Journal of carcinogenesis 20110101

• Changes in gene expression and cellular architecture in an ovarian cancer progression model.

  PloS one 20110101

• Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities.

  Journal of oncology 20110101

• Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study.

  Radiation oncology (London, England) 20110101

• Cambogin is preferentially cytotoxic to cells expressing PDGFR.

  PloS one 20110101

• Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells.

  BMC cancer 20110101

• Picomolar dichotomous activity of gnidimacrin against HIV-1.

  PloS one 20110101

• Targeted treatment for chronic lymphocytic leukemia.

  OncoTargets and therapy 20110101

• Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis.

  Molecular cancer therapeutics 20101201

• [Chemotherapy and targeted treatments in glioblastomas].

  Neuro-Chirurgie 20101201

• Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101201

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.

  Breast cancer research and treatment 20101101

• Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

  Current oncology reports 20101101

• Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101101

• Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors.

  Cancer science 20101001

• Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.

  Molecular cancer therapeutics 20101001

• Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules.

  British journal of cancer 20100907

• Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.

  International journal of radiation oncology, biology, physics 20100801

• The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.

  Gynecologic oncology 20100701

• A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701

• Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.

  Neuro-oncology 20100601

• A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100501

• Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100501

• Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients.

  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20100501

• Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.

  Molecular cancer therapeutics 20100501

• Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.

  Clinical lung cancer 20100501

• Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.

  Leukemia & lymphoma 20100401

• Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100301

• Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301

• Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301

• Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.

  Talanta 20100215

• A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.

  Neuro-oncology 20100201

• Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

  The Journal of biological chemistry 20100108

• Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).

  Current drug targets 20100101

• Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70.

  Leukemia 20100101

• Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis.

  American journal of physiology. Gastrointestinal and liver physiology 20100101

• Enzastaurin induces H2AX phosphorylation to regulate apoptosis via MAPK signalling in malignant glioma cells.

  European journal of cancer (Oxford, England : 1990) 20100101

• Protein kinase Calpha: disease regulator and therapeutic target.

  Trends in pharmacological sciences 20100101

• MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.

  BMC cancer 20100101

• Molecular profiling of endometrial malignancies.

  Obstetrics and gynecology international 20100101

• Progress on antiangiogenic therapy for patients with malignant glioma.

  Journal of oncology 20100101

• Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

  Journal of oncology 20100101

• LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.

  BMC cancer 20100101

• Cellular responses to Cisplatin-induced DNA damage.

  Journal of nucleic acids 20100101

• Signal transduction inhibitor therapy for lymphoma.

  Hematology. American Society of Hematology. Education Program 20100101

• A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.

  Investigational new drugs 20091201

• Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20091201

• Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.

  Anticancer research 20091201

• Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090901

• Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation.

  Translational oncology 20090818

• Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.

  Cancer chemotherapy and pharmacology 20090801

• Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology.

  The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20090701

• Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.

  Molecular cancer therapeutics 20090701

• Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.

  Cancer research 20090615

• Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer.

  International journal of colorectal disease 20090601

• Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths.

  Journal of medicinal chemistry 20090528

• Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.

  Cancer letters 20090518

• A phase I trial of enzastaurin in patients with recurrent gliomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090515

• [Role of PKCbeta in the malignant tumors and enzastaurin, a PKCbeta inhibitor].

  Yao xue xue bao = Acta pharmaceutica Sinica 20090501

• Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents.

  Mini reviews in medicinal chemistry 20090401

• PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

  Blood 20090319

• Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.

  Hematological oncology 20090301

• Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.

  Cancer research 20090215

• Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.

  Blood 20090212

• Antiangiogenic drugs in ovarian cancer.

  British journal of cancer 20090113

• In vivo/ex vivo and in situ assays used in cancer research: a brief review.

  Toxicologic pathology 20090101

• Role of PKCbeta in hepatocellular carcinoma cells migration and invasion in vitro: a potential therapeutic target.

  Clinical & experimental metastasis 20090101

• Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.

  Head & neck oncology 20090101

• Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.

  Journal of biopharmaceutical statistics 20090101

• In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography.

  Journal of oncology 20090101

• Current available therapies and future directions in the treatment of malignant gliomas.

  Biologics : targets & therapy 20090101

• MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.

  Journal of carcinogenesis 20090101

• Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

  British journal of cancer 20081202

• Exploring multi-targeting strategies for the treatment of gliomas.

  Current opinion in investigational drugs (London, England : 2000) 20081201

• Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.

  Translational oncology 20081201

• Waldenstrom macroglobulinemia.

  Cancer letters 20081018

• Protein kinase C beta in malignant pleural mesothelioma.

  Anti-cancer drugs 20081001

• [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001

• The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells.

  Cancer letters 20080908

• Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.

  British journal of cancer 20080902

• Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL.

  Journal of neurochemistry 20080901

• Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

  Biologics : targets & therapy 20080901

• Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.

  British journal of cancer 20080805

• The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.

  Leukemia & lymphoma 20080701

• Current aspects of targeted therapy in head and neck tumors.

  European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 20080701

• Targeted treatment and new agents in diffuse large B-cell lymphoma.

  Seminars in hematology 20080701

• Circulating endothelial cells in oncology: pitfalls and promises.

  British journal of cancer 20080603

• Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells.

  Investigational new drugs 20080601

• Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C.

  European journal of cancer (Oxford, England : 1990) 20080601

• Enzastaurin.

  Expert opinion on investigational drugs 20080601

• Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.

  Molecular cancer therapeutics 20080601

• Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.

  Cancer research 20080315

• Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion.

  Cancer science 20080301

• Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301

• Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.

  Investigational new drugs 20080201

• A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080201

• Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs.

  European journal of haematology 20080101

• A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.

  Anti-cancer drugs 20080101

• Protein kinase C isozymes as therapeutic targets for treatment of human cancers.

  Advances in enzyme regulation 20080101

• Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.

  The oncologist 20080101

• Reduction of HLA-DR+ lymphocytes after treatment with enzastaurin in patients with metastatic thyroid cancer.

  Chemotherapy 20080101

• [Protein kinases C: a new cytoplasmic target].

  Bulletin du cancer 20080101

• Novel therapies in breast cancer: what is new from ASCO 2008.

  Journal of hematology & oncology 20080101

• A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma.

  Clinical medicine. Oncology 20080101

• Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071115

• Enzastaurin.

  Current opinion in oncology 20071101

• Chemoradiotherapy in malignant glioma: standard of care and future directions.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070910

• Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.

  Journal of clinical pharmacology 20070901

• Enzastaurin, a targeted PKCBeta inhibitor, in relapsed or refractory DLBCL: a promising new strategy based on gene expression signature.

  Current oncology reports 20070901

• Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Survival improvement in thoracic cancer: progress from the last decade and beyond.

  Lung cancer (Amsterdam, Netherlands) 20070801

• Lessons learned in the development of targeted therapy for malignant gliomas.

  Molecular cancer therapeutics 20070701

• Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.

  Blood 20070601

• Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments.

  Investigational new drugs 20070601

• Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501

• Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

  Blood 20070215

• Synergistic antiglioma activity of radiotherapy and enzastaurin.

  Annals of neurology 20070201

• Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.

  Current treatment options in oncology 20070201

• Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas.

  Biology direct 20070101

• Inorganic pyrophosphate generation by transforming growth factor-beta-1 is mainly dependent on ANK induction by Ras/Raf-1/extracellular signal-regulated kinase pathways in chondrocytes.

  Arthritis research & therapy 20070101

• What is the right dose? The elusive optimal biologic dose in phase I clinical trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901

• Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901

• The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.

  The Journal of investigative dermatology 20060701

• Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.

  Molecular cancer therapeutics 20060701

• Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

• American Association for Cancer Research--97th annual meeting.

  IDrugs : the investigational drugs journal 20060601

• Perspectives in central nervous system malignancies.

  IDrugs : the investigational drugs journal 20060601

• Protein kinase C-beta as a therapeutic target in breast cancer.

  Seminars in oncology 20060601

• Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.

  International journal of clinical pharmacology and therapeutics 20051201

• The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.

  Cancer research 20050815

• The evolution of cancer research and drug discovery at Lilly Research Laboratories.

  Advances in enzyme regulation 20050101

• Hypoxia, tumor endothelium, and targets for therapy.

  Advances in experimental medicine and biology 20050101

• Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.

  Bioorganic & medicinal chemistry letters 20030602

• Antiangiogenic effects of a protein kinase Cbeta-selective small molecule.

  Cancer chemotherapy and pharmacology 20020101